Ovarian Neoplasm Epithelial
12
3
5
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.7%
2 terminated out of 12 trials
33.3%
-53.2% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (12)
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Sub-type Specific Genomic Mutations in sBOTs
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Functional Analysis of BRCAness
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Pharmacokinetic Study of Tranexamic Acid
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
Inherited Susceptible Genes Among Epithelial Ovarian Cancer